Axsome Therapeutics(AXSM)
搜索文档
Axsome Therapeutics(AXSM) - 2019 Q4 - Earnings Call Transcript
2020-03-13 02:05
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2019 Earnings Conference Call March 12, 2020 8:00 AM ET Company Participants Mark Jacobson - COO Herriot Tabuteau - CEO Cedric O'Gorman - SVP of Clinical Development and Medical Affairs Dave Marek - Chief Commercial Officer Nick Pizzie - CFO Conference Call Participants Charles Duncan - Cantor Fitzgerald Ram Selvaraju - HC Yatin Suneja - Guggenheim Partners Marc Goodman - SVB Matt Kaplan - Ladenburg Bert Hazlett - BTIG Myles Minter - William Blair Operator Good mor ...
Axsome Therapeutics(AXSM) - 2019 Q3 - Earnings Call Transcript
2019-11-08 20:55
Axsome Therapeutics, Inc (NASDAQ:AXSM) Q3 2019 Earnings Conference Call November 7, 2019 8:00 AM ET Company Participants Mark Jacobson - SVP of Operations at Axsome Therapeutics Herriot Tabuteau - Chief Executive Officer Cedric O'Gorman - SVP of Clinical Development and Medical Affairs David Marek - Chief Commercial Officer Nick Pizzie - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Yatin Suneja - Guggenheim Joon Lee - SunTrust Robinson Humphrey Robert Hazlett - BTI ...
Axsome Therapeutics(AXSM) - 2019 Q3 - Quarterly Report
2019-11-08 06:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45- ...
Axsome Therapeutics(AXSM) - 2019 Q2 - Quarterly Report
2019-08-09 04:49
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-42419 ...
Axsome Therapeutics(AXSM) - 2019 Q2 - Earnings Call Transcript
2019-08-09 00:38
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2019 Results Earnings Conference Call August 8, 2019 8:00 AM ET Company Participants Mark Jacobson - SVP of Operations at Axsome Therapeutics Herriot Tabuteau - Chief Executive Officer Cedric O'Gorman - SVP of Clinical Development and Medical Affairs Nick Pizzie - Chief Financial Officer Conference Call Participants Marc Goodman - SVB Leerink Joon Lee - SunTrust Robinson Humphrey Raghuram Selvaraju - H.C. Wainwright Robert Hazlett - BTIG Matt Kaplan - Ladenburg Tha ...
Axsome Therapeutics(AXSM) - 2019 Q1 - Earnings Call Transcript
2019-05-10 13:01
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2019 Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Mark Jacobson - Senior Vice President, Operations Dr. Herriot Tabuteau - Chief Executive Officer Dr. Cedric O'Gorman - Senior Vice President, Clinical Development and Medical Affairs Nick Pizzie - Chief Financial Officer Conference Call Participants Marc Goodman - SVB Leerink Ram Selvaraju - H.C. Wainwright Maria Skoboleva - Cantor Fitzgerald Matt Kaplan - Ladenburg Thalmann Bert Hazlett - BT ...